Bacteriemia por Sphingomonas paucimobilis en pacientes pediátricos y adultos de un hospital de referencia del Perú 2020-2024

Stalin Vilcarromero; Olguita del Águila; Mario Agramonte-Vilca; Norka Luarte-Saldaña

doi:10.17843/rpmesp.2026.431.14786

Authors

Stalin Vilcarromero Hospital Nacional Edgardo Rebagliati Martins, EsSalud. Lima, Perú https://orcid.org/0000-0002-9097-0638
Olguita del Águila Hospital Nacional Edgardo Rebagliati Martins, EsSalud. Lima, Perú https://orcid.org/0000-0003-3085-0148
Mario Agramonte-Vilca Hospital Nacional Edgardo Rebagliati Martins, EsSalud. Lima, Perú. Universidad San Antonio Abad del Cusco, Cusco, Perú https://orcid.org/0000-0003-1023-0689
Norka Luarte-Saldaña Hospital Nacional Edgardo Rebagliati Martins, EsSalud. Lima, Perú https://orcid.org/0009-0007-8381-8121

DOI:

https://doi.org/10.17843/rpmesp.2026.431.14786

Keywords:

Bacteremia, Drug Resistance, Hospital-Acquired Infection, Central Venous Catheters

Abstract

Sphingomonas paucimobilis is a ubiquitous, low-virulence bacterium that can cause bacteremia, especially in immunocompromised patients. Given the lack of recent reports on this pathogen and its resistance profile in Peru, this series evaluated its clinical and microbiological characteristics in a referral hospital. Six cases confirmed by blood culture between January 2020 and September 2024 were analyzed (four pediatric, two adult). All patients presented with multiple risk factors or comorbidities, with most using a central venous catheter. The observed mortality rate in the series was 50%. Regarding susceptibility, two isolates showed resistance to third- and fourth-generation cephalosporins and ciprofloxacin, while all were susceptible to aminoglycosides and another quinolone, levofloxacin. S. paucimobilis represents an emerging pathogen, with variable resistance patterns that highlight the need for continuous surveillance and individualized therapeutic management guided by antibiogram.

Downloads

Download data is not yet available.

References

Ionescu MI, Neagoe D Ștefan, Crăciun AM, Moldovan OT. The Gram-Negative Bacilli Isolated from Caves—Sphingomonas paucimobilis and Hafnia alvei and a Review of Their Involvement in Human Infections. Int J Environ Res Public Health. 2022;19(4):2324. doi: 10.3390/ijerph19042324.

Laupland KB, Paterson DL, Stewart AG, Edwards F, Harris PNA. Sphingomonas paucimobilis bloodstream infection is a predominantly community-onset disease with significant lethality. Int J Infect Dis. 2022;119:172-7. doi: 10.1016/j.ijid.2022.03.060.

Bavaro DF, Mariani MF, Stea ED, Gesualdo L, Angarano G, Carbonara S. Sphingomonas paucimobilis outbreak in a dialysis room: Case report and literature review of an emerging healthcare associated infection. Am J Infect Control. 2020;48(10):1267-9. doi: 10.1016/j.ajic.2020.01.018.

Aşkın FN, Erinmez M, Ören AC, Manay AB, Zer Y. Sphingomonas paucimobilis outbreak at a pediatric hematology-oncology hospital: Epidemiological investigation and literature review of an emerging healthcare-associated infection. Jpn J Infect Dis. 2022;75(4):374-81. doi: 10.7883/yoken.JJID.2021.661.

Cornejo A, Gomes C, Suarez L, Martinez-Puchol S, Bustamante P, Pons MJ, An unidentified cluster of infection in the Peruvian Amazon region. J Infect Dev Ctries. 2015;9(05):524-9. doi: 10.3855/jidc.6235.

Benevides GN, Hein N, Lo DS, Ferronato AE, Ragazzi SLB, Yoshioka CRM, et al. Otomastoiditis caused by Sphingomonas paucimobilis: case report and literature review. Autopsy Case Rep. 2014;4(3):13-20. doi: 10.4322/acr.2014.024.

Beaino ME, Fares J, Malek A, Hachem R. Sphingomonas paucimobilis-related bone and soft-tissue infections: A systematic review. Int J Infect Dis. 2018;77:68-73. doi: 10.1016/j.ijid.2018.09.021.

Rohilla R, Raina D, Singh M, Pandita AK, Patwal S. Evaluation of Sphingomonas paucimobilis as an emerging nosocomial pathogen in a teaching hospital in Uttarakhand. Iran J Microbiol. 2021; Available from: https://publish.kne-publishing.com/index.php/IJM/article/view/7425. doi:10.18502/ijm.v13i5.7425.

Vaz-Moreira I, Nunes OC, Manaia CM. Diversity and Antibiotic Resistance Patterns of Sphingomonadaceae Isolates from Drinking Water. Appl Environ Microbiol. 2011;77(16):5697-706. doi: 10.1128/AEM.00579-11. ciencia.ucp.pt+1.

Ministerio de Salud del Perú. Norma técnica de salud para la vigilancia, prevención y control de las infecciones asociadas a la atención de salud (IAAS). Lima: MINSA; 2020. 84 p.

O’Grady NP. Prevention of Central Line–Associated Bloodstream Infections. N Engl J Med. 2023 21;389(12):1121-31. doi: 10.1056/NEJMra2213296.

Organización Panamericana de la Salud. Protocolo para el fortalecimiento de la vigilancia de la resistencia a los antimicrobianos basada en aislamientos en las Américas: primera fase, hemocultivos [Internet]. Washington, D.C.: OPS; 2021. Available from: https://iris.paho.org/handle/10665.2/53258.